Immunological characterization of peripheral blood samples inpatients with pulmonary cachexia

MU Klinikum, Medizinische Klinik und Poliklinik V0 sites80 target enrollmentJuly 9, 2024

Overview

No summary available.

Registry

who.int

Start Date

July 9, 2024

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

MU Klinikum, Medizinische Klinik und Poliklinik V

•underlying disease currently assumed to be stable, no emergency treatment with hospitalization \>24 h in the last 4 weeks
•\- no antibiotic or hematopoietic (G\-CSF) treatment in the last 4 weeks
•\- patient is able to read and answer questionnaires
•\- patient is able to perform lung function and diffusion measurement
•\- Patient able to perform a hand force measurement

•\- patient age \<18 years, patient not capable of giving informed consent
•\- unclear primary diagnosis (e.g.: suspected COPD, inclusion in the study can be reconsidered if the diagnosis is confirmed)
•\-severe known comorbidity associated with the development of cachexia, e.g. second malignancy, HIV infection (exception: concomitant COPD in NSCLC)
•\- Lack of weight gain during childhood development with a long\-term low BMI \<20 kg/m2
•\- known serious eating disorder, e.g. anorexia nervosa
•\- currently desired weight loss, e.g. as part of a diet
•\- anamnestic or documented Covid\-19 infection within the last month
•\- pregnancy
•\- known critical anemia (Hb \<8 g/dl)
•\- known high\-grade cardiac arrhythmia